abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb
Article

1 Nov 2006

Author:
Novartis

[DOC] Statement by Novartis [see para. 4 for comments regarding lawsuit brought in India]

In...India, Novartis provides Glivec totally free of charge to …99% of all patients receiving the medicine...Worldwide to…more than 17,000 patients…[T]he generic versions of Glivec in India are priced at approximately 4.5 times the average annual income...Helping patients and promoting access begins with developing new and innovative medicines …and the best way to encourage innovation is by respecting intellectual property.

Part of the following timelines

MSF [Médecins Sans Frontières] urges Novartis to drop its case against the Indian Government

India: Novartis challenges patent law - seeks extended protection for cancer drug, saying "patents save lives"; NGOs say move threatens affordable essential medicines